News

A recent study found that patients with PBC who do not respond to OCA within one year may have a higher risk of adverse effects.

Gut bacteria may play an important role in how primary biliary cholangitis (PBC) starts and worsens, according to a recent review.

When researchers administered obeticholic acid to mice with liver disease, they released high levels of the inflammatory protein HMGB1.

The amount of bile duct loss at the time of diagnosis appears to closely correlate with prognosis in patients with PBC.

Itching negatively impacts patients’ quality of life and work productivity in PBC, but there is currently no way to manage it effectively.

Peroxisome proliferator-activated receptor (PPAR) agonists appear to be a safe and effective therapeutic alternative for patients with PBC.

In a postmarketing clinical trial, patients with noncirrhotic PBC receiving Ocaliva showed significantly higher rates of liver transplant and death.

For patients, these initiatives mean greater visibility for their condition, more resources to navigate care, and stronger bonds with others who understand their experience.

A new study finds that verbal suggestions about a task can influence how willing people with PBC may be to persist through fatigue.

A recent study utilized genetic markers demonstrate that individuals with higher BMI may have a higher risk of developing PBC.